Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

WILLIAM'S HEMATOLOGY > 104 Plasma Cell Neoplasms: General Considerations > Flashcards

104 Plasma Cell Neoplasms: General Considerations Flashcards

1
Q

Characterized by the same primary genetic mutations as in myeloma but do not cause end-organ damage and represent a precursor condition with an average 1%/year risk of progression into myeloma, AL amyloidosis or, more rarely, other lymphoproliferative disorders.

A

MGUS

The prevalence of FLC-only MGUS is 0.8% in the general population.

It progresses to myeloma in a minority of patients at the rate of 0.3% per year

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Nonmodifiable, major risk factors for MGUS

A

Advanced age, male gender (twofold higher incidence), and African descent

OTHER RISK FACTORS:
Immunocompromised state and occupational exposures to wood and leather manufacturing, asbestos, fertilizers, and pesticides

A family history of MGUS or myeloma in a first-degree relative doubles the risk of developing MGUS.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Nearly 50% of patients with MGUS have PCs with translocations involving the IGH locus on chromosome __________ and most commonly one of these five partner loci: 11q13 (cyclin D1 gene), 4q16 (FGFR-2 and MMSET), 6q21 (CCND3), 16q23 (c-maf), and 20q11 (maf-B).

A

Chromosome 14q32

The biological events underlying the progression of MGUS to myeloma are undetermined, and there is no single gene mutation or molecular signature predictive of neoplastic transformation.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Compared with MGUS, SM carries a ________ times higher risk of progression to myeloma in the first 5 years after diagnosis.

A

10
(10% per year)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

TRUE OR FALSE

No molecular or chromosomal abnormalities can distinguish between monoclonal gammopathy, SM, or myeloma at the time of diagnosis.

A

TRUE

No molecular or chromosomal abnormalities can distinguish between monoclonal gammopathy, SM, or myeloma at the time of diagnosis.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Secondary genetic events occur in much higher frequencies in myeloma, such as:

A

p53 deletions, especially in refractory and extramedullary presentations
N-RAS and K-RAS mutations,
Chromosome 1p deletion
Gain of 1q21
Translocations involving MYC (8q24).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

TRUE OR FALSE

There is an increased relative risk of monoclonal gammopathy and myeloma in overweight and obese patients as determined by their body mass index (BMI).

A

TRUE

There is an increased relative risk of monoclonal gammopathy and myeloma in overweight and obese patients as determined by their body mass index (BMI).

Adiponectin serum concentrations were lower in patients with monoclonal gammopathy who subsequently developed myeloma.

Obese individuals have been shown to have shorter telomeres than nonobese individuals.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Fat tissue is a principal source of _____________, one of the principal growth and antiapoptotic cytokines acting on myeloma cells.

A

Interleukin (IL)-6

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

TRUE OR FALSE

Aspirin promotes proliferation and induces apoptosis of myeloma cell lines in vitro through regulation of BCL-2 and BAX and suppression of vascular endothelial growth factor (VEGF).

A

FALSE

Aspirin inhibits proliferation and induces apoptosis of myeloma cell lines in vitro through regulation of BCL-2 and BAX and suppression of vascular endothelial growth factor (VEGF).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

The most important alterations during myeloma development

A

Decreases of the B-cell receptor (BCR) and the chemokine receptors CXCR5, and CCR7

In contrast, PCs upregulate CXCR4, CD138, and CD38.

PCs also undergo changes to transcription factors highlighted by a decrease in PAX5, CIITA, and EBF.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Represents the most commonly inactivated tumor-suppressor gene in MM

A

p53

p53 mutations are negatively correlated with survival

30% of patients with PC leukemia present with p53 mutations

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

The HIV protease inhibitor and ER stressor that has shown activity in overcoming bortezomib resistance in bortezomib-refractory patients in phase I and II clinical studies

A

Nelfinavir

OTHER PREDICTORS OF DRUG RESISTANCE

Expression of CRBN is therefore necessary for IMiDs to exert their antimyeloma activity, and CRBN downregulation has been reported as an escape mechanism in myeloma patients treated with IMiDs.

CD55 and CD59 levels were significantly higher at the time of progression, suggesting their role in mediating daratumumab resistance

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

The gold standard for the detection and classification of myeloma.

A

Fluorescence in situ hybridization (FISH)

Cytogenetic abnormalities, using FISH, are observed in more than 90% of patients with myeloma.

However, FISH cannot provide information about chromosomal abnormalities without the use of large-scale panels of probes.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Hyperdiploid cytogenetic :

Primary genetic mutations are mutually exclusive, and patients with myeloma can be broadly divided into those with hyperdiploidy and those with IgH translocations.

A

Trisomies of many odd-numbered chromosomes, namely, 3, 5, 7, 9, 15, 19, and 21

Associated with a favorable outcome and considered standard risk cytogenetics.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

IgH translocations

A

Translocations at the IGH loci (14q32), t(4;14), t(14;16), and t(14;20)

Considered high-risk cytogenetics

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

________drives the overexpression of cyclin D1, is no longer considered a high-risk cytogenetic feature, and is predictive of response to a BCL2 inhibitor.

A

t(11;14)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Secondary cytogenetic abnormalities and are associated with unfavorable prognosis

A

Chromosome 17p/17 and 1q

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART)

Standard-risk group

A

t(6;14) or the t(11;14) translocation
hyperdiploid group

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART)

Intermediate-risk group

A

t(4;14) translocation and deletions of chromosome 13 or hypodiploidy

deletion of chromosome 13 by metaphase cytogenetics (not by FISH)

Noncytogenetic factor considered intermediate risk: PC labeling index equal or higher than 3%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART)

High-risk group

A

t(14;16) or the t(14;20) translocation or deletion 17p13

Noncytogenetic factor considered high risk: high-risk GEP signature

mSMART does not include deletion of chromosome 1p or gain of chromosome 1q in the current stratification.

Both are considered adverse prognostic factors in myeloma, and their occurrence appears in later stages of the disease.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

TRUE OR FALSE

Chromosomal aberrations in AL need to be assessed by FISH analysis and conventional metaphase cytogenetics.

A

FALSE

Chromosomal aberrations in AL need to be assessed by FISH analysis and not by conventional metaphase cytogenetics.

The clonal PC burden in AL is usually small and similar to that seen in patients with MGUS.

Proliferation rate of PCs is very low

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Approximately 80% of patients with AL have FISH abnormalities, the most common being

A

t(11;14)

Detected in 45% to 60% of patients with AL amyloidosis

Other chromosomal abnormalities seen in patients with AL include other IgH translocations, deletion 13/13q–, deletion 17, and gain(1q)

Deletion 17p13 is not seen in this form of amyloidosis.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

TRUE OR FALSE

In particular, t(11;14) is associated with same prognosis in amyloidosis and in myeloma, in which it is associated with a good prognosis and is a predictive factor of poor response to bortezomib-based regimens.

A

FALSE

In particular, t(11;14) is associated with an inferior prognosis in amyloidosis in contrast to myeloma, in which it is associated with a good prognosis and is a predictive factor of poor response to bortezomib-based regimens.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

The main cytokines involved in increased bone resorption and suppressed bone formation lead to OLs in patients with myeloma

A

IL-6, receptor activator of NF-κB ligand (RANKL)/osteoprotegerin (OPG), BAFF, chemokine (C-C motif) ligand 3 (CCL3)–macrophage inflammatory protein (MIP)-1α, and VEGF

Increased bone resorption and suppressed bone formation lead to OLs in patients with myeloma.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

An inhibitor of the WNT signaling pathway

Inhibits osteoblast (OB) differentiation and promotes osteoclast (OC) maturation

A

DKK1

26
Q

A DKK1-blocking antibody, proved to be an effective therapeutic agent to halt myeloma-related bone disease in preclinical and early-phase clinical studies; however, its clinical development was halted

A

BH880

27
Q

One of the most important regulatory systems for homeostatic bone remodeling

A

RANK–RANKL-OPG pathway

28
Q

A membrane-anchored signaling receptor of the TNF receptor family, is expressed on OC precursors

Induces osteoclastogenesis and activation of mature OCs

A

RANK

29
Q

A soluble member of the TNF receptor family, is also produced by OBs and BMSCs

It blocks RANK-dependent OC maturation and activation.

A

OPG

The marrow plasma of myeloma patients contains elevated levels of RANKL and reduced levels of OPG, consistent with an osteoclast-enriched TME.

Also, low serum levels of OPG correlate with advanced MBD in patients with myeloma.

30
Q

A myeloma cell–promoting member of the TNF superfamily of proteins that is expressed by OCs and BMSCs.

A

B-CELL ACTIVATION FACTOR (BAFF)

Significantly increased in the serum of patients with myeloma

31
Q

A member of the TGF-β superfamily of proteins, activates a signaling pathway that results in phosphorylation of SMADs

A stimulator of osteoclastogenesis and is overexpressed in patients with myeloma

A

Activin A

IL-3, another stimulator of OCs, can induce the secretion of activin A by resident macrophages in the myeloma marrow microenvironment, providing a mechanism for the upregulation of activin A in patients with myeloma.

32
Q

The root cause of relapse/refractory disease in myeloma

A

Presence of a less differentiated, myeloma stem cell that is not adequately eradicated by current treatment approaches

There is no agreement on the specific phenotype of the myeloma stem cell, but side-population (SP) cells, which constitute a minor fraction of the myeloma cells, have the features of stem cells.

Have greater clonogenic potential and drug resistance

33
Q

Myeloma stem cells are drug-resistant subpopulation of memory B-cell–like cells with the ff pheonytype

A

CD138–/CD19+/CD27+ phenotype

34
Q

TRUE OR FALSE

The CD138– cell population derived from myeloma cell lines contains significantly higher levels of aldehyde dehydrogenase, a marker for stem cells.

A

TRUE

The CD138– cell population derived from myeloma cell lines contains significantly higher levels of aldehyde dehydrogenase, a marker for stem cells.

The CD138– cells were not affected by the drugs typically used in myeloma, such as lenalidomide, bortezomib, dexamethasone, and cyclophosphamide.

35
Q

Pathognomonic features of PC disorders

A

Capacity for secreting large amount of monoclonal proteins in the serum and urine

The monoclonal protein is either an intact Ig or its FLC.

36
Q

The most common M-protein isotype in myeloma

A

IgG

Followed by IgA and rarely IgM

37
Q

The most common screening test to identify a serum M protein

A

Serum protein electrophoresis (SPEP) with immunofixation electrophoresis (IFE)

38
Q

TRUE OR FALSE

The quantity of M protein produced per cell reflect the Ig synthetic load of myeloma

A

FALSE

The quantity of M protein produced per cell does not entirely reflect the Ig synthetic load of myeloma

Cells tend to be less efficient in folding than normal PC and secrete a relatively decreased amount of M protein per cell.

In addition, the more immature and more proliferative myeloma cells are, the less Ig per cell per day they secrete

39
Q

What is the light chain escape phenomenon

A

The decreased quality control, and the increased proteotoxicity burden of synthesis and folding of the heavy chain—> Myeloma cells only secrete FLCs in the absence of a heavy chain.

40
Q

TRUE OR FALSE

Under physiologic conditions, κ-producing PCs are twice as abundant as λ-producing PCs.

A

TRUE

Under physiologic conditions, κ-producing PCs are twice as abundant as λ-producing PCs.

κ FLCs typically circulate as monomers and are renally cleared twice as efficiently as dimeric λ FLC, resulting in a physiologic κ/λ ratio around 1.147

41
Q

TRUE OR FALSE

The half-life of serum FLCs is much shorter than that of the intact Ig (3–6 hours vs 21 days), serial serum FLCs allow early assessment of successful disease cytoreduction compared with SPEP.

A

TRUE

The half-life of serum FLCs is much shorter than that of the intact Ig (3–6 hours vs 21 days), serial serum FLCs allow early assessment of successful disease cytoreduction compared with SPEP.

42
Q

TRUE OR FALSE

Patients with high levels of FLC and rapid reduction upon cytoreductive therapy have been identified as a high-risk group with a poor outcome.

A

TRUE

Patients with high levels of FLC and rapid reduction upon cytoreductive therapy have been identified as a high-risk group with a poor outcome.

43
Q

An independent prognostic factor for progression of myeloma in monoclonal gammopathy and SM.

A

Serum FLC ratio

FLCs have also been incorporated into the updated Mayo 2012 staging for AL amyloidosis.

44
Q

Use to to identify the nature of the M protein and to quantify Ig levels

A

Immunofixation electrophoresis (IFE)

45
Q

Many of the IgA and some of the IgG myelomas have their M spike in the

A

β-globulin region

46
Q

TRUE OR FALSE

If an M protein is identified on SPEP and IFE does not identify the heavy chain, quantitative analysis of IgD and IgE should be performed.

A

TRUE

If an M protein is identified on SPEP and IFE does not identify the heavy chain, quantitative analysis of IgD and IgE should be performed.

47
Q

Most IgD myelomas are associated with _____ light chains.

A

λ light chains

48
Q

Used to to assess the extent of proteinuria and discriminate between albuminuria and Bence Jones (BJ) proteinuria

A

24-hour urine collection for urine protein electrophoresis (UPEP) and IFE

In contrast to the serum FLCs, monitoring of urine FLCs is less reliable and difficult to interpret and is therefore not routinely used.

49
Q

In a normal marrow with normal cellularity, there may be up to _______% nonclonal PCs present

A

2% to 5%

However, the percentage of PCs can be much higher in reactive marrows and hypoplastic or aplastic marrows in the absence of a PCN.

In normal marrow, there can be some clustering of PCs around the blood vessels. However, the presence of larger clusters of PCs away from the blood vessels should alert one to the possibility of PCN, especially myeloma.

50
Q

A monoclonal antibody and a specific immune marker for PCs

A

CD138

In situ hybridization for cytoplasmic κ and λ should be used to assess clonality.

51
Q

The best gating strategy in flow cytometry uses

A

CD38, CD138, CD45, and light-scatter

When used for MRD, at least 100 neoplastic PC events should be acquired.

The percentage of PCs detected by flow cytometry is typically an underestimate of real marrow plasmacytosis.

52
Q

_____ is negative on normal PCs but is often positive on myeloma cells

A

CD56

The opposite is true for CD19

CD117 and CD20, which are negative on normal PCs and can be aberrantly expressed on myeloma cells

CD28 and CD200 are negative or only weakly expressed on normal PCs but can be strongly positive on myeloma cells

CD27 and CD81 are strongly expressed on normal PCs but weak or negative on myeloma cells.

53
Q

In a skeletal x-ray survey, at least ___________% of trabecular bone must be lost to see a lytic lesion.

A

50% to 75%

54
Q

TRUE OR FALSE

A skeletal survey is not an adequate technique to assess response to treatment or to diagnose early recurrence of myeloma before new lesions occur

A

TRUE

A skeletal survey is not an adequate technique to assess response to treatment or to diagnose early recurrence of myeloma before new lesions occur

The sensitivity and specificity of a skeletal survey is low

Skeletal survey is not an adequate technique to assess response to treatment or to diagnose early recurrence of myeloma before new lesions occur.

55
Q

More sensitive imaging techniques for diagnosis and monitoring of myeloma

A

18F-fluorodeoxyglucose (FDG) positron emission tomography–computed tomography (PET/CT) and MRI

MRI should include the axial bones containing active hematopoiesis in adults (skull, spine, sternum, shoulders and upper humeri, pelvis, and upper femora)

56
Q

It allows assessment of myeloma-related disease, including bone structures and extramedullary sites.

A

18F-Fluorodeoxyglucose Positron Emission Tomography–Computed Tomography

57
Q

A small protein that associates with human leukocyte antigen class I and is almost exclusively catabolized in the kidneys

One of the most important prognostic factors in myeloma

A

β2-Microglobulin

The main source of β2m in the serum is membrane turnover.

Its level reflects tumor load and renal function

58
Q

Typically reflects de-differentiated myeloma with plasmablastic features and is predictive of a poor prognosis.

A

Serum Lactic Dehydrogenase

High LDH levels were associated with hypercalcemia, elevated serum β2m levels, extramedullary manifestations, plasmablastic morphology, and short OS duration

59
Q

Only test approved by the FDA for clinical use in myeloma to assess MRD

A

NGS

60
Q

IMWG has defined MRD negativity as:

A

Absence of marrow PCs at the level of 10–5
Imaging negativity as PET/CT negative
Sustained MRD negativity as MRD negative status lasting for at least 1 year

WILLIAM'S HEMATOLOGY (109 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions